M Soukop
Overview
Explore the profile of M Soukop including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soukop M, Robinson A, Soukop D, Ingham-Clark C, Kelly M
Colorectal Dis
. 2007 Jan;
9(2):146-50.
PMID: 17223939
Objective: Over the last 6 years, multidisciplinary teams (MDTs) have been established and play a key role in organizing the delivery of cancer care in the UK. There are no...
2.
Johnston S, Gumbrell L, Evans T, Coleman R, Smith I, Twelves C, et al.
Cancer Chemother Pharmacol
. 2004 Jan;
53(4):341-8.
PMID: 14722733
Idoxifene is a novel selective oestrogen receptor modulator (SERM) which had greater binding affinity for the oestrogen receptor (ER) and reduced agonist activity compared with tamoxifen in preclinical studies. In...
3.
Clamp A, Blackhall F, Vasey P, Soukop M, Coleman R, Halbert G, et al.
Br J Cancer
. 2003 Oct;
89(7):1152-4.
PMID: 14520436
Bryostatin-1 is a macrocyclic lactone whose main mechanism of action is protein kinase C modulation. We investigated its activity as a weekly 24-h infusion in recurrent ovarian carcinoma. In all,...
4.
Evans T, Pentheroudakis G, Paul J, McInnes A, Blackie R, Raby N, et al.
Ann Oncol
. 2002 Aug;
13(9):1469-78.
PMID: 12196374
Background: The purpose of this study was to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose of capecitabine when used in combination with epirubicin and cisplatin (ECC) in patients...
5.
Pentheroudakis G, Lim K, Dunlop D, Soukop M, Eatock M
Acta Oncol
. 2002 Feb;
40(7):855-61.
PMID: 11859986
To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in...
6.
MacKay H, McInnes A, Paul J, Raby N, Lofts F, McDonald A, et al.
Ann Oncol
. 2002 Jan;
12(10):1407-10.
PMID: 11762812
Background: The aim of this study was to evaluate the efficacy of the combination of epirubicin, cisplatin and ralitrexed (Tomudex). ECT, in patients with advanced oesophageal or gastric adenocarcinoma. Efficacy...
7.
Blackhall F, Ranson M, Radford J, Hancock B, Soukop M, McGown A, et al.
Br J Cancer
. 2001 Mar;
84(4):465-9.
PMID: 11263437
Bryostatin 1 is a naturally occurring macrocyclic lactone with promising antitumour and immunomodulatory function in preclinical and phase I clinical investigations. In this phase II study, 17 patients with progressive...
8.
de Bono J, Fraser J, Lee F, Simpson A, Lim C, Naik S, et al.
Ann Oncol
. 2000 Aug;
11(6):749-52.
PMID: 10942066
A 37-year-old man who had successfully undergone cardiac transplantation for dilated cardiomyopathy presented with a history of severe pain over his left shoulder, rib cage and thoracic spine. Clinical examination...
9.
Taylor P, Jackson G, Galloway M, Soukop M, Tinegate H, Angus B, et al.
Cancer Chemother Pharmacol
. 2000 Jul;
46(1):63-8.
PMID: 10912580
Purpose: The majority of patients with low-grade non-Hodgkin's lymphoma (LGNHL) are in the older age groups and are thus less able to tolerate aggressive treatment. Chlorambucil, alone and in combination,...
10.
Eatock M, Anthony D, Wilson P, Paul J, Smith M, Soukop M, et al.
Br J Cancer
. 2000 Jun;
82(12):1925-31.
PMID: 10864199
The standard treatment for advanced gastro-oesophageal cancer in the UK is epirubicin, cisplatin and continuous infusion 5-fluoruracil by an indwelling central venous catheter (ECF), which has significant morbidity. Raltitrexed (tomudex),...